**Score:** 7/10  
**Verdict:** almost

Ready to continue full-scale experiments: yes. The implementation is now cleaner, auditable, label-aware, and broad enough to justify scaling.

Ready for paper-level claims: no, except narrow claims like "the CONFIRM benchmark pipeline runs end-to-end, separates expected small effects from null/stress labels, and rejects staged synthetic/site-confounded false confirmations after the full gate stack."

I verified the reported counts against `combined_benchmark_results.json`, inspected `labels.py` and `run_multimodal_benchmark.py`, and reran tests: `13 passed`.

**Ranked Critical Weaknesses**

1. **Headline FCR is now semantically cleaner but easier to satisfy.** Moving cognition/small-effect claims out of FCR is defensible, but `0/12` is not a global false-confirmation rate over all attempted claims. Minimum fix: report FCR, small-positive recovery, and candidate confirmation as co-primary stratified metrics, with an explicit table showing every excluded/uncertain label and why.

2. **Benchmark breadth improved, but scientific breadth is still shallow.** Most new positives are age/sex split-half stability controls, not disease or clinically meaningful multimodal claims. Minimum fix: add adjudicated AD and psychosis claims with real diagnosis/symptom labels, or explicitly frame the current benchmark as controls-only plus candidate disease probes.

3. **Replication is doing most of the false-confirmation cleanup.** Several nulls survive through `+multiverse`; the full FCR becomes zero only after replication. Minimum fix: add naturally occurring tasks where confound, power, and multiverse gates each independently change verdicts, not just synthetic traps.

4. **CIs remain too wide for top-venue claims.** Full-gate FCR `0/12` has upper CI about `0.265`; multimodal negative denominator is only 5. Minimum fix: expand to roughly 30-50 adjudicated negative/stress claims and separate them by synthetic, site-confounded, underpowered, and literature-null classes.

5. **Label ledger is useful but not yet authoritative.** The first-pass literature ledger is a good correction, not expert adjudication. Minimum fix: freeze a formal label table with DOI/cohort/modality/phenotype/effect-size prior/confidence and ideally independent reviewer signoff.

6. **Multimodal replication is mostly split-half, not external cohort replication.** NACC/PANStudy split-half results are useful engineering checks but weaker than cross-cohort validation. Minimum fix: add external cohort replication for at least one AD and one psychosis/multimodal claim.

**Were The Next Steps Implemented Correctly?**

Mostly yes. The label-aware scoring change is directionally correct, PANStudy disease claims were correctly avoided, and the NACC/PANStudy adapter honestly reports missing diagnosis mappings rather than inventing them.

What would be misleading: presenting this as "multimodal disease validation," "broad neuroimaging false discovery control," or "FCR solved." The honest claim is narrower: the pipeline is now ready for larger, better-labeled experiments; it is not yet ready to support broad paper-level claims.
